RATIONALE: Small airway (bronchioles less than 2 mm in diameter) means less than 10% of total airway resistance. In despite of it is not commonly used at clinical practice because its variability, its dysfunction has been closely linked with severity of asthma (both with symptoms and with respiratory tests).
Johns Hopkins University, Baltimore, MD. RATIONALE: Bronchiectasis are knowingly associated with lung infections, however, additional respiratory conditions may contribute to their development. Accordingly, we aimed to identify respiratory comorbidities associated with bronchiectasis in patients with CVID. METHODS: We conducted a cross-sectional analysis of 869 CVID cases in the USIDNET registry. The main outcome was physician-reported bronchiectasis. Demographic and clinical characteristics were compared using chi-square or Wilcoxon-Mann-Whitney tests. Logistic regression models were built to evaluate associations between respiratory comorbidities and bronchiectasis. RESULTS: There were 121 CVID patients with bronchiectasis. Affected individuals were significantly older (median age 52 yr. vs. 45 yr. in group without bronchiectasis, p50.0001) and had lower serum IgA (median IgA 11 mg/dL vs. 29.5 mg/dL in unaffected patients, p50.0179). Our analyses showed that sinusitis (OR52.29 95%CI 1.26, 4.16), pneumonia (OR53.66 95%CI 2.20, 6.08), lung abscesses (OR53.73 95%CI 1.11, 12.52) and bronchiolitis obliterans (BO) (OR56.49 95%CI 2.09, 20.14) were associated with increased odds of having bronchiectasis. In contrast, upper airway inflammatory conditions (allergic and non-allergic), inflammatory lower respiratory complications (e.g. granulomas, nodules, interstitial lung disease/pneumonia, GLILD, etc.) as well as lower airway disease (e.g. asthma, bronchitis, COPD) failed to demonstrate associations with bronchiectasis. CONCLUSIONS: Our findings showed that not only lower but upper respiratory infections (sinusitis) and BO are independently associated with bronchiectasis in CVID. Our study has limitations (cross-sectional, risk of recall/selection/attrition bias) but nonetheless, examines a large patient population and motivates further investigation into a relevant topic. Early detection and treatment of respiratory coexisting conditions may contribute to prevent the development of bronchiectasis in CVID patients. University of Kansas Medical Center, Kansas City, KS. RATIONALE: Specific Antibody Deficiency (SAD) is a primary immunodeficiency characterized by normal immunoglobulins with deficient response to polysaccharide antigen vaccination. Currently there is a lack of consensus regarding the management of this disease. The aim of this study was to determine whether there was a statistically significant difference in rate of infections in patients diagnosed with SAD who were managed with IVIG, prophylactic antibiotics, and clinical observation. METHODS: We conducted a retrospective review of 26 patients recruited from the University of Kansas Medical Center with the diagnosis of SAD who were above the age 18. We determined the rate of antibiotic prescriptions per year for patients with SAD treated with immunoglobulin supplementation, prophylactic antibiotic, or clinical observation. RESULTS: There was a significant rate of decreased antibiotic prescriptions in patients treated with IVIG (n511, p50.002) or prophylactic antibiotics (n55, p50.001) versus those clinically observed (n511) using a paired t test. The mean difference in antibiotic prescriptions in those patients treated with IVIG versus prophylactic antibiotics was not statistically significant (p50.254) using an analysis of covariance. The mean IgG level was 914 among all the patients. The mean number of years followed post intervention was 1.25. CONCLUSIONS: In patients diagnosed with SAD, there was a notable difference in infection rate between treatment with either IVIG or prophylactic antibiotics versus clinical observation. However, there was no notable difference in infection rate between IVIG and prophylactic antibiotics. Prophylactic antibiotic therapy for patients with SAD may serve to be more cost effective and practical approach to management.
